New thioureas and related substances intended for melanoma targeting.
Thiouracil and a few related drugs are known to be melanoma-seeking agents owing to specific incorporation into nascent melanin. The melanin-affinic properties are apparently due to binding to intermediates, preferably dopaquinone, produced in the melanin synthetic pathway by tyrosinase-catalysed oxidation of tyrosine. In the present paper, in vitro screening methods have been used for the identification of possible melanoma seekers according to the above principle. The binding of test substance to dopaquinone suppressed dopachrome formation by the withdrawal of dopaquinone from the reaction of the mixture, and the decrease in dopachrome concentration was monitored spectrophotometrically at 475 nm. In order to eliminate false results caused by tyrosinase inhibition, which also will decrease the dopachrome concentration, the oxygen consumption was followed potentiometrically. To avoid the effect of tyrosinase inhibition on dopachrome formation, additional experiments with autoxidation of L-dopa in the presence of test substance were performed. Of the 22 substances (mainly thioureylenes and thioamides) studied, 4,5,6-triamino-2(H)- pyrimidinehtionsulfate, trithiocyanuric acid, 2-thiouracil, 6-methyl-2-thiouracil, and 4- amino-2-mercaptopyrimidine most effectively decreased the dopachrome formation with no or little inhibition of tyrosinase activity. They should therefore be regarded as potential melanoma seekers. In a complementary autoradiographic study on the uptake of the potent tyrosinase inhibitor mercaptobenzothiazole (MBT) in B 16 melanoma transplanted to mice, it was found that strong tyrosinase inhibition seems to decrease incorporation into melanin in vitro. MBT was partially accumulated in restricted areas of the tumor which may be explained by the molar dose injected.
Mårs
U
U
Department of Pharmaceutical Biosciences, Uppsala University, Sweden.
Larsson
B S
BS
D000818:Animals; D001345:Autoradiography; D001487:Basidiomycota / Q000201:enzymology; D016227:Benzoquinones / Q000378:metabolism / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D015259:Dopamine Agents / Q000378:metabolism / Q000494:pharmacology; D019746:Intramolecular Oxidoreductases; D007535:Isomerases / Q000378:metabolism; D007980:Levodopa / Q000378:metabolism / Q000494:pharmacology; D008543:Melanins / Q000378:metabolism; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice; D008810:Mice, Inbred C57BL; D014442:Monophenol Monooxygenase / Q000037:antagonists & inhibitors; D009368:Neoplasm Transplantation; D010084:Oxidation-Reduction; D013890:Thiourea / Q000378:metabolism / Q000494:pharmacology*; D014916:Whole-Body Irradiation
D016227:Benzoquinones; D015259:Dopamine Agents; D008543:Melanins; D007980:Levodopa; D004295:Dihydroxyphenylalanine; C035157:dopaquinone; D014442:Monophenol Monooxygenase; D007535:Isomerases; D019746:Intramolecular Oxidoreductases; C042501:dopachrome isomerase; D013890:Thiourea